AG
CNCE

Advisor Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Advisor Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-575
Closed -$6K – 4677
2016
Q3 		$6K Hold
575
– – ﹤0.01% 3843
2016
Q2 		$6K Buy
+575
New +$7.32K ﹤0.01% 3728

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Advisor Group's CNCE Position: Q4 2016 in Review

Advisor Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2016, closing a stake of 575 shares — an estimated $6K sold.

Advisor Group first reported a position in CNCE in Q2 2016 and held it in 2 quarters. The position peaked at $6K in Q3 2016. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

  • Advisor Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Advisor Group sold 575 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $6K.
  • Advisor Group first reported a position in Concert Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
  • Advisor Group's Concert Pharmaceuticals, Inc. position peaked at $6K in Q3 2016.
  • 89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on Advisor Group's 13F filing for Q4 2016, filed 31 Jan 2017.